TABLE 1.
Source and cohort no. | Infectiona | No. of patients | No. of samples |
---|---|---|---|
Confounding infection pilot studyb | |||
1 | Aspergillus | 20 | 20 |
2 | Chlamydia | 20 | 20 |
3 | Mycoplasma | 19 | 19 |
4 | Normal | 31 | 31 |
VF training set | 18 | 18 | |
Valley fever patient sera with non-VF controlsc | |||
1 | VF training set (U of A) | 35 | 55 |
2 | VF test set (U of A) | 25 | 67 |
3 | Normal individuals (ASU) | 41 | 41 |
4 | Influenza vaccinees (2006-2007 seasonal vaccine) (ASU) | 7 | 7 |
U of A, University of Arizona; ASU, Arizona State University.
The samples for the confounding infection pilot study were obtained from SeraCare Life Sciences (Milford, MA).
The samples from the VF training set were obtained from John Galgiani, MD, Valley Fever Center for Excellence (Tucson, AZ).